Compare ARMOUR Residential REIT, Inc. (ARR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARMOUR Residential REIT, Inc. vs Sana Biotechnology Inc — how do they compare? ARMOUR Residential REIT, Inc. trades at $16.73 (market cap $2.07B), while Sana Biotechnology Inc trades at $3.81 (market cap $1.13B). The key difference: ARMOUR Residential REIT, Inc. is the larger of the two by market cap, and ARMOUR Residential REIT, Inc. pays a 17.28% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ARR | SANA | |
|---|---|---|
Market Cap | $2.07B | $1.13B |
Sector | Financials | Health |
52-Week High | $19.12 | $5.92 |
52-Week Low | $14.05 | $2.68 |
Dividend Yield | 17.28% | — |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARMOUR Residential REIT (ARR) trades at $16.74, up 1.18% with neutral technical signals. The REIT shows strong profitability with 97.43% net income margin and attractive valuation at P/E of 3.78 and P/B of 0.91. Recent Q2 2026 earnings beat expectations at $0.72 per share versus $0.69 estimate. The company maintains consistent dividend payments with recent $0.24 distributions. Cash flow trends show operational stability despite significant investing activities.
ARR presents value opportunity with deep discount to book value and high dividend yield, though mixed earnings performance and heavy mortgage-backed securities exposure create volatility risk. Analyst consensus remains cautious with 60% hold rating, reflecting balanced outlook between attractive valuation and sector-specific headwinds.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
